ZA200207538B - Use of fulvestrant in the treatment of resistant breast cancer. - Google Patents
Use of fulvestrant in the treatment of resistant breast cancer. Download PDFInfo
- Publication number
- ZA200207538B ZA200207538B ZA200207538A ZA200207538A ZA200207538B ZA 200207538 B ZA200207538 B ZA 200207538B ZA 200207538 A ZA200207538 A ZA 200207538A ZA 200207538 A ZA200207538 A ZA 200207538A ZA 200207538 B ZA200207538 B ZA 200207538B
- Authority
- ZA
- South Africa
- Prior art keywords
- treatment
- fulvestrant
- breast cancer
- substance
- composition
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 44
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title claims description 37
- 229960002258 fulvestrant Drugs 0.000 title claims description 36
- 206010006187 Breast cancer Diseases 0.000 title claims description 25
- 208000026310 Breast neoplasm Diseases 0.000 title claims description 22
- 239000000203 mixture Substances 0.000 claims description 35
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 24
- 239000003886 aromatase inhibitor Substances 0.000 claims description 19
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 15
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 15
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 15
- 229960001603 tamoxifen Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 229960002932 anastrozole Drugs 0.000 claims description 8
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical group N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims 11
- 238000009472 formulation Methods 0.000 description 20
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000004044 response Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000262 estrogen Substances 0.000 description 9
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229940011871 estrogen Drugs 0.000 description 8
- 239000000328 estrogen antagonist Substances 0.000 description 8
- 229940046836 anti-estrogen Drugs 0.000 description 7
- 230000001833 anti-estrogenic effect Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 102000015694 estrogen receptors Human genes 0.000 description 7
- 108010038795 estrogen receptors Proteins 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 6
- 229960003881 letrozole Drugs 0.000 description 6
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 6
- 229960003437 aminoglutethimide Drugs 0.000 description 5
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 5
- 229940066675 ricinoleate Drugs 0.000 description 5
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 229940046844 aromatase inhibitors Drugs 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 206010066901 Treatment failure Diseases 0.000 description 3
- 229960002903 benzyl benzoate Drugs 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000003637 steroidlike Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101000889443 Homo sapiens Trefoil factor 1 Proteins 0.000 description 1
- 102100039175 Trefoil factor 1 Human genes 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000007469 bone scintigraphy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003439 radiotherapeutic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008172.9A GB0008172D0 (en) | 2000-04-05 | 2000-04-05 | Therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200207538B true ZA200207538B (en) | 2003-12-19 |
Family
ID=9889101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200207538A ZA200207538B (en) | 2000-04-05 | 2002-09-19 | Use of fulvestrant in the treatment of resistant breast cancer. |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20030158166A1 (enExample) |
| EP (2) | EP1272195B1 (enExample) |
| JP (1) | JP2003528919A (enExample) |
| KR (1) | KR100757764B1 (enExample) |
| CN (1) | CN1431905A (enExample) |
| AT (1) | ATE306270T1 (enExample) |
| AU (2) | AU2001244372B2 (enExample) |
| BR (1) | BR0109789A (enExample) |
| CA (1) | CA2403608A1 (enExample) |
| CH (1) | CH1272195H1 (enExample) |
| CZ (1) | CZ303096B6 (enExample) |
| DE (1) | DE60113975T2 (enExample) |
| DK (1) | DK1272195T3 (enExample) |
| EE (1) | EE05026B1 (enExample) |
| ES (1) | ES2248300T3 (enExample) |
| GB (1) | GB0008172D0 (enExample) |
| HU (1) | HU230064B1 (enExample) |
| IL (2) | IL151932A0 (enExample) |
| IS (1) | IS2869B (enExample) |
| MX (1) | MXPA02009744A (enExample) |
| NO (1) | NO329949B1 (enExample) |
| NZ (1) | NZ539603A (enExample) |
| PL (1) | PL201175B1 (enExample) |
| RU (1) | RU2265438C2 (enExample) |
| SK (1) | SK287779B6 (enExample) |
| UA (1) | UA80388C2 (enExample) |
| WO (1) | WO2001074366A1 (enExample) |
| ZA (1) | ZA200207538B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0116620D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| CA2453111A1 (en) * | 2001-07-07 | 2003-01-23 | Alan Marshall Irving | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| EP1623713A1 (en) * | 2004-07-09 | 2006-02-08 | Proskelia SAS | Cominations of pure anti-estrogen with aromatase inhibitors |
| US8557863B2 (en) * | 2005-09-27 | 2013-10-15 | Robert Benson Aylor | Suppression and prevention of tumors |
| WO2007062093A2 (en) * | 2005-11-22 | 2007-05-31 | Incyte Corporation | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor |
| US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| US20140161827A1 (en) * | 2011-05-09 | 2014-06-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| CA2836831C (en) | 2011-05-20 | 2015-06-02 | Capital, Business Y Gestion De Finanzas S.L. | Pharmaceutical composition |
| US20160375234A1 (en) * | 2014-01-10 | 2016-12-29 | Atossa Genetic Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
| US9421264B2 (en) * | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| SG11202002105WA (en) | 2017-09-11 | 2020-04-29 | Atossa Therapeutics Inc | Methods for making and using endoxifen |
| WO2019224790A2 (en) * | 2018-05-24 | 2019-11-28 | Kashiv Biosciences, Llc | Prodrugs of fulvestrant |
| JP7662204B2 (ja) | 2019-07-03 | 2025-04-15 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| EP4110344A4 (en) * | 2020-02-29 | 2024-03-13 | The University Of Vermont | Use of thyromimetics for the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
-
2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
-
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en not_active Ceased
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko not_active Expired - Lifetime
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
-
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
-
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69022722T2 (de) | Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen. | |
| EP1250138B1 (en) | Fulvestrant formulation | |
| Mauriac et al. | Fulvestrant (Faslodex™) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials | |
| JP7080117B2 (ja) | 性ステロイド前駆体とｓｅｒｍとの併用による男性アンドロゲン欠乏症状又は疾患の治療 | |
| DE60318447T2 (de) | Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung | |
| KR100757764B1 (ko) | 내성 유방암 치료에서의 풀베스트란트의 용도 | |
| Jones | Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor | |
| AU2001244372A1 (en) | Use of fulvestrant in the treatment of resistant breast cancer | |
| AU2019398768B2 (en) | Medication against estrogen-receptor ß (ERß) positive breast tumor | |
| JP2004510994A (ja) | エストロゲン−感受性疾病の処理のための組み合わせ治療 | |
| Johnston et al. | A cancer research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen | |
| Yoneya et al. | Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels | |
| Estévez et al. | Finding the right dose of fulvestrant in breast cancer | |
| Crnjevic et al. | Harrisons Manual of Oncology 2nd Ed. | |
| BR102020001533A2 (pt) | Duas formulações percutâneas de anastrozol, número cas: 120511-73-1, uma somente com anastrozol para controle de aromatização em câncer de mama, pele, próstatas e outra com anastrozol e testosterona para reposição hormonal com controle de aromatização | |
| HK1051498B (en) | Use of fulvestrant in the treatment of resistant breast cancer | |
| HK1081842A (en) | Use of fulvestrant in the treatment of resistant breast cancer | |
| Shetty et al. | Drug Review-Exemestane: A milestone against breast cancer | |
| Herschler et al. | Aromatase Inhibitors and the Role of Hormonal Therapy in Breast Cancer | |
| HK40004636B (en) | Improved testosterone gel and method of use |